跳至主要内容
临床试验/EUCTR2018-000059-42-FR
EUCTR2018-000059-42-FR进行中(未招募)1 期

Comparison of short infusion versus prolonged infusion of ceftolozane-tazobactam among patients with ventilator associated-pneumonia to Pseudomonas aeruginosa in intensive care units - CEFTOREA

CHU DE TOULOUSE0 个研究点目标入组 60 人开始时间: 2018年4月9日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Age = 18 years
  • patients with ventilator associated-pneumonia to Pseudomonas aeruginosa
  • patients hospitalized in intensive care units
  • Pseudomonas aeruginosa susceptible to ceftolozane-tazobactam
  • SAPS II (Simplified Acute. Physiological Score II) > 20
  • Expected duration of survival > 7 days
  • Informed consent of the patient or, failing that, the patient’s close or trustworthy person
  • Affiliated to a social security scheme or equivalent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 40
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 20

排除标准

  • history of allergy to one of the two molecules
  • history of allergy to betalactamines
  • Strain Isolated resistant to Ceftolozane-Tazobactam combination
  • Renal insufficiency with a glomerular filtration rate evaluated by CKD-EPI < 50 ml/min
  • Patient on dialysis or under continuous hemodiafiltration
  • Pregnant or nursing women
  • Patient benefiting from a system of legal protection for adults

研究者

发起方
CHU DE TOULOUSE

相似试验